IBRX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Immunitybio Inc

NASDAQ | IBRX

2.14

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 5, 2025)

$2.05B

Market Cap

-

P/E Ratio

-0.44

EPS

$5.88

52 Week High

$1.83

52 Week Low

HEALTHCARE

Sector

IBRX Chart

Recent Chart
Price Action

IBRX Technicals

Tags:

IBRX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $15M
Total Revenue $15M
Cost Of Revenue $18M
Costof Goods And Services Sold $18M
Operating Income -$344M
Selling General And Administrative $169M
Research And Development $190M
Operating Expenses $359M
Investment Income Net -
Net Interest Income -$152M
Interest Income $2.4M
Interest Expense $154M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $18M
Income Before Tax -$414M
Income Tax Expense $81K
Interest And Debt Expense -
Net Income From Continuing Operations -$414M
Comprehensive Income Net Of Tax -
Ebit -$259M
Ebitda -$242M
Net Income -$414M

Revenue & Profitability

Earnings Performance

IBRX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $383M
Total Current Assets $185M
Cash And Cash Equivalents At Carrying Value $143M
Cash And Short Term Investments $143M
Inventory $8.3M
Current Net Receivables $2.7M
Total Non Current Assets $198M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $15M
Intangible Assets Excluding Goodwill $15M
Goodwill $910K
Investments -
Long Term Investments $0
Short Term Investments $6.4M
Other Current Assets $24M
Other Non Current Assets -
Total Liabilities $871M
Total Current Liabilities $55M
Current Accounts Payable $6.7M
Deferred Revenue -
Current Debt -
Short Term Debt $8.7M
Total Non Current Liabilities $816M
Capital Lease Obligations $42M
Long Term Debt $462M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $504M
Other Current Liabilities $39M
Other Non Current Liabilities $285M
Total Shareholder Equity -$488M
Treasury Stock -
Retained Earnings -$3.4B
Common Stock $85K
Common Stock Shares Outstanding $700M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$391M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $18M
Capital Expenditures $6.9M
Change In Receivables -
Change In Inventory -$8.3M
Profit Loss -
Cashflow From Investment -$12M
Cashflow From Financing $282M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$414M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $15M
Total Revenue $15M
Cost Of Revenue $18M
Costof Goods And Services Sold $18M
Operating Income -$344M
Selling General And Administrative $169M
Research And Development $190M
Operating Expenses $359M
Investment Income Net -
Net Interest Income -$152M
Interest Income $2.4M
Interest Expense $154M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $18M
Income Before Tax -$414M
Income Tax Expense $81K
Interest And Debt Expense -
Net Income From Continuing Operations -$414M
Comprehensive Income Net Of Tax -
Ebit -$259M
Ebitda -$242M
Net Income -$414M

IBRX News

IBRX Profile

Immunitybio Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

ImmunityBio, Inc. is a pioneering immunotherapy company focused on developing innovative treatments utilizing memory T-cells to combat a wide range of cancer types. The company's proprietary cancer vaccine aims to create an effective therapeutic approach that minimizes the reliance on high-dose chemotherapy while enhancing the body's immune response against tumors. By leveraging advanced biotechnology, ImmunityBio strives to transform cancer treatment and improve patient outcomes, positioning itself as a key player in the evolving landscape of oncology.

NVVE
+14.42%
$0.24
MTC
+390.13%
$1.49
ASST
+15.20%
$1.44
PFE
-1.45%
$24.30
VHAI
0.00%
$0.00
RIVN
+24.05%
$15.50
LNAI
+60.07%
$1.33
GPUS
+12.96%
$0.39
PLUG
-8.36%
$2.52
NVDA
+1.26%
$201.21
CHR
+8.10%
$0.13
RUBI
-54.40%
$0.27
T
-0.36%
$24.44
SLDP
+52.44%
$8.55
SMX
+47.00%
$2.16
AXDX
-61.36%
$0.03
BYND
-1.87%
$1.30
PLTR
-1.70%
$187.48
TSLA
+3.77%
$461.03
F
+3.63%
$13.25
AMD
+3.62%
$259.11
ADAP
-15.14%
$0.05
DNN
-1.86%
$2.68
WTO
-5.83%
$0.04
AAPL
+0.36%
$270.04
PINS
-22.07%
$25.64
BITF
+2.60%
$3.94
BMNR
-7.93%
$39.46
CIFR
+7.46%
$24.19
INTC
+3.04%
$38.15
SMCI
-9.70%
$42.80
YDKG
-3.51%
$0.05
NFE
+15.54%
$1.55
ONDS
-0.75%
$5.91
RXRX
-0.40%
$4.98
SOFI
+1.48%
$29.80
TEVA
+22.06%
$24.97
RMBL
+60.50%
$3.21
DVLT
-9.55%
$1.61
ADD
-25.47%
$0.05
AAL
+5.91%
$13.39
ACHR
-0.15%
$9.54
ETHD
-13.88%
$4.52
SRM
+53.27%
$10.30
BAC
-1.44%
$52.76
SNAP
+0.06%
$7.47
KVUE
+2.12%
$16.30
EPWK
-7.88%
$0.06
QS
+10.91%
$17.12
FUBO
+9.10%
$4.01
ZDAI
+18.33%
$0.54
NAKA
-11.88%
$0.78
KDLY
-11.88%
$0.78
IREN
+10.35%
$73.53
VALE
+3.05%
$12.30
APLD
-5.50%
$31.06
WLGS
-5.57%
$0.04
WULF
+0.39%
$15.07
TLRY
+3.63%
$1.28
U
+14.50%
$41.07
NVO
-0.87%
$47.82
MARA
+3.29%
$17.16
HIMS
+4.67%
$44.79
BTG
+1.62%
$4.06
GRAB
-0.08%
$5.78
ETWO
0.00%
$3.30
RGTI
+4.81%
$36.87
APPS
+22.90%
$7.27
RIG
+0.76%
$3.93
BURU
-3.24%
$0.28
RDHL
+15.74%
$1.25
NIO
+3.00%
$7.37
NOK
+0.70%
$6.85
CAN
+8.55%
$1.20
BTBT
+2.06%
$3.24
HTZ
-4.60%
$6.42
WBD
+1.77%
$23.00
MU
-7.10%
$218.03
BW
+36.89%
$5.12
AFMD
-34.94%
$0.18
NCLH
-0.01%
$18.78
HBAN
-0.65%
$15.27
AG
-7.48%
$10.69
QBTS
+4.60%
$31.11
RIOT
-3.78%
$18.54
IONZ
-7.06%
$4.15
SOLT
-13.39%
$11.06
PLTZ
+3.12%
$6.25
AMZN
+0.05%
$249.46
NVTS
-7.60%
$9.66
PCG
+1.39%
$16.38
PLTD
+1.65%
$6.45
BBD
+2.81%
$3.50
CMBM
-7.05%
$3.01
MSPR
-24.83%
$0.49
ABEV
+1.04%
$2.41
CMG
+1.15%
$32.10
KLG
-9.05%
$13.35
SOUN
+1.48%
$15.35
JOBY
+3.05%
$15.21
NVVE
+14.42%
$0.24
MTC
+390.13%
$1.49
ASST
+15.20%
$1.44
PFE
-1.45%
$24.30
VHAI
0.00%
$0.00
RIVN
+24.05%
$15.50
LNAI
+60.07%
$1.33
GPUS
+12.96%
$0.39
PLUG
-8.36%
$2.52
NVDA
+1.26%
$201.21
CHR
+8.10%
$0.13
RUBI
-54.40%
$0.27
T
-0.36%
$24.44
SLDP
+52.44%
$8.55
SMX
+47.00%
$2.16
AXDX
-61.36%
$0.03
BYND
-1.87%
$1.30
PLTR
-1.70%
$187.48
TSLA
+3.77%
$461.03
F
+3.63%
$13.25
AMD
+3.62%
$259.11
ADAP
-15.14%
$0.05
DNN
-1.86%
$2.68
WTO
-5.83%
$0.04
AAPL
+0.36%
$270.04
PINS
-22.07%
$25.64
BITF
+2.60%
$3.94
BMNR
-7.93%
$39.46
CIFR
+7.46%
$24.19
INTC
+3.04%
$38.15
SMCI
-9.70%
$42.80
YDKG
-3.51%
$0.05
NFE
+15.54%
$1.55
ONDS
-0.75%
$5.91
RXRX
-0.40%
$4.98
SOFI
+1.48%
$29.80
TEVA
+22.06%
$24.97
RMBL
+60.50%
$3.21
DVLT
-9.55%
$1.61
ADD
-25.47%
$0.05
AAL
+5.91%
$13.39
ACHR
-0.15%
$9.54
ETHD
-13.88%
$4.52
SRM
+53.27%
$10.30
BAC
-1.44%
$52.76
SNAP
+0.06%
$7.47
KVUE
+2.12%
$16.30
EPWK
-7.88%
$0.06
QS
+10.91%
$17.12
FUBO
+9.10%
$4.01
ZDAI
+18.33%
$0.54
NAKA
-11.88%
$0.78
KDLY
-11.88%
$0.78
IREN
+10.35%
$73.53
VALE
+3.05%
$12.30
APLD
-5.50%
$31.06
WLGS
-5.57%
$0.04
WULF
+0.39%
$15.07
TLRY
+3.63%
$1.28
U
+14.50%
$41.07
NVO
-0.87%
$47.82
MARA
+3.29%
$17.16
HIMS
+4.67%
$44.79
BTG
+1.62%
$4.06
GRAB
-0.08%
$5.78
ETWO
0.00%
$3.30
RGTI
+4.81%
$36.87
APPS
+22.90%
$7.27
RIG
+0.76%
$3.93
BURU
-3.24%
$0.28
RDHL
+15.74%
$1.25
NIO
+3.00%
$7.37
NOK
+0.70%
$6.85
CAN
+8.55%
$1.20
BTBT
+2.06%
$3.24
HTZ
-4.60%
$6.42
WBD
+1.77%
$23.00
MU
-7.10%
$218.03
BW
+36.89%
$5.12
AFMD
-34.94%
$0.18
NCLH
-0.01%
$18.78
HBAN
-0.65%
$15.27
AG
-7.48%
$10.69
QBTS
+4.60%
$31.11
RIOT
-3.78%
$18.54
IONZ
-7.06%
$4.15
SOLT
-13.39%
$11.06
PLTZ
+3.12%
$6.25
AMZN
+0.05%
$249.46
NVTS
-7.60%
$9.66
PCG
+1.39%
$16.38
PLTD
+1.65%
$6.45
BBD
+2.81%
$3.50
CMBM
-7.05%
$3.01
MSPR
-24.83%
$0.49
ABEV
+1.04%
$2.41
CMG
+1.15%
$32.10
KLG
-9.05%
$13.35
SOUN
+1.48%
$15.35
JOBY
+3.05%
$15.21
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.